Bank of America’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-65,031
| Closed | -$729K | – | 7504 |
|
|
2017
Q3 | $729K | Sell |
65,031
-9,262
| -12% | -$102K | ﹤0.01% | 4722 |
|
|
2017
Q2 | $817K | Sell |
74,293
-7,984
| -10% | -$79.9K | ﹤0.01% | 4565 |
|
|
2017
Q1 | $806K | Buy |
82,277
+39,508
| +92% | +$395K | ﹤0.01% | 4574 |
|
|
2016
Q4 | $462K | Buy |
42,769
+36,346
| +566% | +$363K | ﹤0.01% | 4852 |
|
|
2016
Q3 | $66K | Sell |
6,423
-2,025
| -24% | -$22.1K | ﹤0.01% | 5622 |
|
|
2016
Q2 | $110K | Sell |
8,448
-5,789
| -41% | -$75.8K | ﹤0.01% | 5481 |
|
|
2016
Q1 | $157K | Sell |
14,237
-1,006
| -7% | -$8.95K | ﹤0.01% | 5271 |
|
|
2015
Q4 | $140K | Sell |
15,243
-17,015
| -53% | -$142K | ﹤0.01% | 5576 |
|
|
2015
Q3 | $224K | Sell |
32,258
-6,905
| -18% | -$59.1K | ﹤0.01% | 5273 |
|
|
2015
Q2 | $385K | Buy |
39,163
+7,284
| +23% | +$66.3K | ﹤0.01% | 4887 |
|
|
2015
Q1 | $283K | Sell |
31,879
-2,641
| -8% | -$21K | ﹤0.01% | 4702 |
|
|
2014
Q4 | $303K | Sell |
34,520
-8,063
| -19% | -$65.3K | ﹤0.01% | 5029 |
|
|
2014
Q3 | $293K | Sell |
42,583
-120,919
| -74% | -$725K | ﹤0.01% | 5049 |
|
|
2014
Q2 | $861K | Buy |
163,502
+19,900
| +14% | +$96.8K | ﹤0.01% | 4114 |
|
|
2014
Q1 | $653K | Buy |
143,602
+125
| +0.1% | +$604 | ﹤0.01% | 4340 |
|
|
2013
Q4 | $723K | Sell |
143,477
-6,501
| -4% | -$31.3K | ﹤0.01% | 4414 |
|
|
2013
Q3 | $760K | Sell |
149,978
-22,239
| -13% | -$124K | ﹤0.01% | 4222 |
|
|
2013
Q2 | $854K | Buy |
+172,217
| New | +$820K | ﹤0.01% | 4209 |
|
Bank of America's SCLN Position: Q4 2017 in Review
Bank of America sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 65,031 shares — an estimated $729K sold.
Bank of America first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $861K in Q2 2014. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Bank of America reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Bank of America sold 65,031 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $729K.
- Bank of America first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Bank of America's Sciclone Pharmaceuticals Inc position peaked at $861K in Q2 2014.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Bank of America's 13F filing for Q4 2017, filed 14 Feb 2018.